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Objectives. The aim of this study was to determine which 
patients will have systolic and diastolic improvement after beta- 
blockade with metoprolol. 
Background. Beta-adrenergic blocking agents improve systolic 
and diastolic function in patients with heart failure. However, it is 
unclear which patients will respond best to therapy. 
Methods. We retrospectively examined baseline characteristics 
of 24 patients who underwent double-blind then open-label treat- 
ment with metoprolol to determine which characteristic predicted 
improvement in systolic and diastolic function. Degree of im- 
provement in systolic function (22 patients) was defined by the 
change in left ventricular ejection fraction after 3 months of 
therapy. Degree of improvement in diastolic function (15 patients) 
was defined as the change in left ventricular end-diastolic pres- 
sure and change in the slope of the isovolumetric relaxation 
rate-end-systolic pressure relation. 
Results. Both systolic blood pressure at baseline (r = 0.54, p = 
0.009) and the maximal positive value of the first derivative of left 
ventricular pressure with respect to time (peak +dP/dt) at 
baseline (r = 0.39, p = 0.07) correlated with improvement in 
ejection fraction after metoprolol treatment. Stepwise logistic 
regression demonstrated that only peak systolic pressure was an 
independent predictor of systolic improvement. Baseline heart 
rate, ventricular volumes, ejection fraction and adrenergic activa- 
tion, as reflected by coronary sinus norepinephrine, did not 
predict response. Patients with the most diastolic impairment at 
baseline had the most favorable diastolic improvement. Those 
with the lowest myocardial respiratory quotient (most fatty acid 
utilization) at baseline also had the most marked reduction in left 
ventricular end-diastolic pressure. 
Conclusions. These data suggest that those patients with the 
highest peak systolic pressure, highest left ventricular end- 
diastolic pressure and most prolonged isovolumetric relaxation at 
baseline will respond best to therapy with metoprolol. However, 
other patients without these characteristics may also benefit. 
(J Am Coil Cardio11995;25:154- 62) 
Beta-adrenergic blocking agents have been shown to improve 
both systolic and diastolic function in patients with dilated 
cardiomyopathy (1-4). However, it is unclear which patients 
will respond best to this novel therapy. It is clear from two 
previous tudies (5,6) that patients with coronary artery disease 
will not respond to beta-blockade as well as patients with 
dilated cardiomyopathy. Two additional studies (7,8) have 
suggested that patients with the highest baseline heart rate, a 
reflection of adrenergic drive to the heart, will respond best to 
beta-blockade. Finally, a recent histologic study (9) of endo- 
myocardial biopsy samples has suggested that patients with the 
least fibrosis will respond best to therapy. The data from this 
last study implied that patients with the greatest amount of 
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residual nonfibrotic tissue (least amount of scar) would re- 
spond most favorably to this therapy. Unfortunately, it is not 
feasible to perform a biopsy in each patient before therapy. 
Because acomprehensive and systematic examination of which 
baseline factors predict systolic and diastolic function improve- 
ment has not been performed, we retrospectively examined 
baseline characteristics of 24 patients who underwent double- 
blind then open-label treatment with metoprolol. We exam- 
ined which baseline characteristics were most predictive of 
systolic and diastolic improvement with therapy. On the basis 
of the previous histologic study (9), our hypothesis was that 
those patients with the greatest contractile reserve would have 
the greatest improvement in systolic function after beta- 
blockade. 
Methods  
Between December 1, 1990 and April 14, 1993, 25 male 
patients (mean [_+SD] age 48 _+ 10 years, range 34 to 75) with 
angiographic nonischemic heart failure were randomized in 
double-blind manner to receive ither metoprolol (n = 15) or 
placebo (n = 10) for a period of 3 months. The details of this 
prospective, double-blind study have been previously pub- 
lished (3). All patients underwent cardiac catheterization at
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baseline and after therapy with metoprolol or placebo at the 
Dallas Veterans Administration Medical Center. All patients 
had a left ventricular ejection fraction -<0.45 before study entry 
and were in New York Heart Association functional classes II 
to IV. One of the 25 original patients (randomized to receive 
placebo) who did not return for a second cardiac atheteriza- 
tion and was lost to follow-up was excluded from analysis. 
After 3 months of therapy, all patients were titrated onto 
open-label metoprolol and underwent radionuclide l ft ven- 
triculography at6 months after randomization. 
All medications were allowed, except beta-blocker therapy 
within 3 months of entry. All patients were taking constant 
doses of angiotensin-converting e zyme inhibitors. All medi- 
cations remained unchanged during the study period except for 
diuretic drugs, which were altered as clinically indicated. 
Written informed consent was obtained from each patient, and 
the protocol was approved by the Human Studies Subcommit- 
tee of the Dallas Veterans Administration and University of 
Texas Southwestern Medical Centers in November 1990. 
ltemodynamie measurement. Each study was performed 
using previously published techniques (2,3). A 7F Wilton- 
Webster coronary sinus thermodilution catheter was placed in 
the coronary sinus for sampling blood and determining coro- 
nary flow. A 7F thermodilution pulmonary artery catheter was 
placed in the pulmonary artery. An 8F double-chip Millar 
micromanometer pigtail catheter was positioned in the left 
ventricle to record left ventricular and aortic pressure. 
Before administration of contrast medium, two coronary 
sinus and two left ventricular heparinized samples were drawn 
simultaneously for blood gas determination. Baseline coronary 
sinus thermodilution measurements, left heart pressure re- 
cordings and cardiac output measurements were performed. 
Atrial pacing (to match heart rate at baseline and 3 months) 
was then initiated to eliminate alterations in contractility and 
relaxation due to changes in heart rate from baseline to 3 
months. Repeat pressures and cardiac output were measured 
followed by digital ventriculography (3). 
After these measurements were recorded, loading condi- 
tions were altered by graded doses of intravenous sodium 
nitroprusside while maintaining pacing to achieve a reduction 
of 15 to 25 mm Hg in aortic end-systolic pressure. Repeat 
simultaneous ventriculograms and hemodynamic recordings 
were performed at one or two time points after aortic end- 
systolic pressure had been altered. Because left ventriculogra- 
phy may increase nd-diastolic pressure transiently, there was 
a delay of at least 10 min between ventriculograms to allow the 
left ventricle to return to equilibrium. 
After 3 months of therapy, the same procedure was used 
with care to match the original atrially paced heart rate used in 
the baseline study. All patients had selective coronary arteriog- 
raphy at the end of their first catheterization to exclude 
significant coronary disease as a cause of their cardiomyopathy. 
Drug titration. Metoprolol or placebo in a 3:2 randomiza- 
tion was initiated on the day after initial catheterization in all 
patients in a double-blind fashion. The drug was titrated 
weekly at the following doses: 6.25, 12.5, 25 and 50 mg twice 
daily. All patients randomized to receive metoprolol tolerated 
titration to full dosage. 
We crossed over all of the placebo-treated patients to 
open-label metoprolol after the repeat (3-month) catheteriza- 
tion. We performed radionuclide ventriculography 6 months 
after randomization (i.e., after 3 months on open-label meto- 
prolol) to assess the change in left ventricular ejection fraction 
after crossover to active drug. Because we had no knowledge of 
who received active drug in the initial 3 months, all patients 
were titrated or retitrated according to the previous titration 
schedule. 
Hemodynamic data analysis. Ventricular volumes were 
measured by analysis of digital left ventriculography using 
standard area-length methods (3,10,11). The cardiac cycle 
selected was not a premature beat or post-premature b at. 
Simultaneous left ventricular pressure recordings were inter- 
faced directly onto the digital volume assessment a  each data 
point in the cardiac cycle. Intraobserver and interobserver 
variability of our digital ventriculographic measurements have 
been published elsewhere (2). 
Assessment of systolic performance. To assess the change in 
left ventricular ejection fraction in all patients after 3 months 
of therapy, the change in left ventricular ejection fraction was 
defined in the 15 patients randomized toreceive metoprolol as 
the change in ejection fraction between baseline and repeat 
catheterization at 3 months. For the nine patients randomized 
to receive placebo, the change in left ventricular ejection 
fraction was defined as the change in ejection fraction between 
the 3-month repeat catheterization a d the 6-month radionu- 
clide study (i.e., 3 months after crossover to open-label meto- 
prolol). Thus, change in ejection fraction was assessed as a 
continuous variable. 
Left ventricular stroke work (LVSW) was determined by 
the following formula (12): 
LVSW = (MSLVP - MDP) x SV x 0.0136, 
where MSLVP = mean systolic left ventricular pressure; 
MDP = mean diastolic left ventricular pressure; and SV = 
stroke volume by thermodilution (cardiac output/heart rate). 
Minute work = LVSW x Heart rate. 
End-systolic elastance. The slope of the end-systolic 
pressure-volume relation was calculated using previously pub- 
lished methods (2,3,13,14). 
Arterial elastance. Arterial elastance was determined by a 
previously validated formula (15,16): Ea = Pes/SV, where 
Ea = arterial elastance; Pes = end-systolic pressure; and SV = 
stroke volume. 
Assessment of diastolic performance. Left ventricular end- 
diastolic pressure was measured by averaging the left ventric- 
ular pressure measurements from 20 to 25 beats at the point 
just before an increase in the first derivative of left ventricular 
pressure with respect to time (+dP/dt) (just before the rapid 
increase in systolic pressure after the a wave). No beat was a 
premature or post-premature b at. 
Isovolumetric relaxation. Left ventricular relaxation was 
assessed by analyzing changes in the time constant of exponen- 
156 EICHHORN ET AL. JACC Vol. 25, No. 1 
PREDICTORS OF IMPROVEMENT WITH BETA-BLOCKERS January, 1995:154-62 
tial isovolumetric pressure decrease (tau) uncorrected for 
afterload (3,17,18) and the slope of the tau-end-systolic pres- 
sure relation (18). Because this relation is linear (18), tau was 
analyzed at each covariate point (end-systolic pressure) over a 
large range of pressures before and after nitroprusside admin- 
istration ( -50 to 75 points/assessment). A linear regression 
analysis of the tau versus end-systolic pressure relation with 
slope R was then determined. 
Tau was determined by a previously described method 
(3,17,18). Because the 9 placebo-treated patients did not 
undergo repeat catheterization after crossover to open-label 
metoprolol, we only assessed predictors of diastolic improve- 
ment in the 15 patients who were initially randomized to 
receive metoprolol. 
Determination f myocardial respiratory quotient. Myocar- 
dial respiratory quotient (RQ), a reflection of myocardial 
substrate utilization (3,19), was determined by left ventricular 
and coronary sinus blood gas determinations (3) and calcu- 
lated according to the oxygen and carbon dioxide content: 
RQ = (CSco 2 - Aco2)/(Ao2 - CSo2)  , 
where Aco 2 and CSco2 = arterial and coronary sinus carbon 
dioxide content, respectively, and Ao 2 and CSo 2 = arterial and 
coronary sinus oxygen content, respectively. The carbon diox- 
ide content of the blood specimens was calculated as follows 
(20): 
CO2 content (retool/liter) 
= (Pco2 [mm Hg])(0.0301 [mmol/liter per mm Hg]) 
+ HCO3- (retool/liter), 
where Pco  2 = partial pressure of carbon dioxide; and HCO 3 = 
bicarbonate. Oxygen content was calculated as follows: 
O2 content (ml/dl) 
= (O2 sat %)(1.36 ml Ojg Hgb)(Hgb [g/all]); 
02 content (retool/liter) 
= {(O2 content [ml/dl])(10 dl/liter)}/(22.4 ml/mmol), 
where sat = saturation; and Hgb = hemoglobin. Variability of 
our respiratory quotient measurements has been tested by 
repeated analysis of measurements from seven patient studies 
of respiratory quotient aken 30 s apart (14 samples) (r = 0.68, 
SEE 0.14, p = 0.0072). 
Radionuclide scan at 6 months. After completion of he- 
modynamic analysis at 3 months after randomization, all 
patients were titrated onto open-label metoprolol. All patients 
were then asked to undergo radionuclide ventriculography 6 
months after randomization. Two placebo-treated patients did 
not have the 6-month scan: one died suddenly before the scan, 
and the other was intolerant to metoprolol titration (after 
crossover) because of severe heart failure. Radionuclide ven- 
triculography was performed and analyzed in blinded manner 
using previously described methodology (21,22). 
Table 1. Univariate and Multivariate Analysis of Improvement in 
Left Ventricular Ejection Fraction After Treatment With 
Metoprolol in 24 Patients 
Baseline Characteristic No. of Pts r Value p Value 
End-diastolic pressure 22 0.07 0.76 
Peak systolic pressure 22 0.54 0.009* 
Tau (isovolumic relaxation rate) 21 0.13 0.59 
End-diastolic volume 22 0.04 0.87 
End-systolic volume 22 0.04 0.87 
Coronary sinus norepinephrine 22 0.003 0.99 
Heart rate 22 0.11 0.62 
Stroke work 22 0.17 0.45 
Peak +dP/dt 22 0.39 0.07 
Myocardial respiratory quotient 22 0.04 0.84 
Ejection fraction 22 0.19 0.40 
End-systolic elastance 20 0.06 0.80 
Arterial elastance 22 0.27 0.23 
*p < 0.05 by multivariate analysis. +dP/dt = first derivative of left ventricular 
pressure with respect totime (maximal positive value); Pts = patients. 
Statistical analysis. Changes in systolic (left ventricular 
ejection fraction) and diastolic (left ventricular end-diastolic 
pressure and R) performance were compared with 13 baseline 
characteristics of the 24 patients by linear (univariate) regres- 
sion analysis. After determination of the univariate predictors 
of systolic and diastolic improvement, he most significant 
predictors (i.e., p < 0.10) were subjected to analysis by 
stepwise multiple regression (univariate predictors tepped in 
one at a time) to assess the relative contribution of each 
predictor. As an additional analysis for systolic improvement, 
we treated change in ejection fraction as a dichotomous rather 
than a continuous variable. Baseline characteristics of patients 
who had an increase in ejection fraction ->0.05 were compared 
with those who did not by an unpaired t test. Because 9 of the 
24 patients randomized in this study were taking placebo for 
the 1st 3 months of the study and then crossed over to 
metoprolol from 3 to 6 months after randomization, change in 
ejection fraction was assessed from baseline to 3 months for 
the metoprolol-treated patients and from 3 to 6 months in the 
placebo-treated patients (i.e., after crossover to active drug). 
Because diastolic improvement was assessed by catheterization 
criteria, only the 15 patients originally randomized to receive 
metoprolol were assessed. Significance was taken as p < 0.05. 
All values are expressed as mean value + 1 SD. 
Resu l ts  
Predictors of systolic improvement. Univariate and multi- 
variate predictors of improvement in left ventricular ejection 
fraction are shown in Table 1. Only peak systolic pressure (r = 
0.54, p = 0.009) and peak +dP/dt (r = 0.39, p = 0.07) were 
univariate predictors of improvement in left ventricular ejec- 
tion fraction (Fig. 1). Stepwise logistic regression analysis 
demonstrated that only peak systolic pressure (p = 0.02) was 
an independent predictor of improvement in ejection fraction. 
Peak +dP/dt (p = 0.33) added no additional predictive value 
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Figure 1. Baseline peak systolic pressure was the most predictive 
indicator of which patients would have an improved left ventricular 
ejection fraction (EF) after metoprolol therapy. Baseline peak maxi- 
mal positive value of the first derivative ofleft ventricular p essure with 
respect o time (+dP/dt) was weakly correlated but was not an 
independent predictor. 
to peak systolic pressure. Contrary to the results of earlier 
studies (7,8), adrenergic activation, as reflected by coronary 
sinus norepinephrine and heart rate, did not predict response 
(Fig. 2). Chamber size, as reflected by left ventricular volumes, 
and ejection fraction also did not predict response to meto- 
prolol (Fig. 2). The metabolic status of the left ventricle, 
manifested by the transmyocardial respiratory quotient, also 
did not predict response to metoprolol. 
When ejection fraction was treated as a dichotomous 
variable, there was a trend toward higher systolic pressure in 
those with (>-0.05, n = 15) than without (109 _+ 17 vs. 94 _+ 
15 mm Hg, p = 0.06) an improved ejection fraction. There was 
also a greater peak +dP/dt in those with than without (877 _+ 
201 vs. 692 _+ 177 mm Hg/s, p = 0.05) an improved ejection 
fraction. 
Predictors of diastolic improvement. Univariate and mul- 
tivariate predictors of improvement in left ventricular end- 
diastolic pressure and myocardial relaxation (R) are shown in 
Table 2. We analyzed two related assessments of diastolic 
function because end-diastolic pressure is most important 
clinically, whereas myocardial relaxation (R) is most represen- 
tative of improvement in myocyte and chamber function (23). 
Several candidate predictors, including baseline left ventricular 
end-diastolic pressure (r = 0.77, p = 0.0008), isovolumetric 
relaxation rate (r = 0.60, p -- 0.02), left ventricular end-systolic 
volume (r = 0.47, p = 0.08) and myocardial respiratory 
quotient (r = 0.59, p = 0.02), were univariate predictors of 
change in left ventricular end-diastolic pressure (Fig. 3). 
However, only baseline left ventricular end-diastolic pressure 
(p = 0.0003) was an independent predictor of change in left 
ventricular end-diastolic pressure. Thus, the higher the base- 
line end-diastolic pressure, the more end-diastolic pressure 
was reduced with metoprolol. There was a univariate relation 
between baseline respiratory quotient and change in end- 
diastolic pressure suggesting that the greater the relative free 
fatty acid utilization of the heart at baseline (relative to 
carbohydrate), the greater the reduction in end-diastolic pres- 
sure after administration fmetoprolol. However, this was not 
an independent predictor (p = 0.3) in the multivariate model. 
Several candidate predictors, including baseline left ventric- 
ular end-diastolic pressure (r = 0.76, p = 0.0017), isovolumet- 
ric relaxation rate (r = 0.70, p = 0.006), slope of the tau-end- 
systolic pressure relation (R) (r = 0.64, p = 0.013), left 
ventricular end-diastolic volume (r = 0.50, p = 0.07), left 
ventricular end-systolic volume (r = 0.60, p = 0.025) and 
myocardial respiratory quotient (r = 0.49, p = 0.08), were 
univariate predictors of change in R (Fig. 4). However, only 
baseline left ventricular end-diastolic pressure (p = 0.002) was 
an independent predictor by stepwise multivariate analysis. 
Thus, the higher the left ventricular end-diastolic pressure at 
baseline, the greater the reduction in R (improvement in 
relaxation) with metoprolol. 
Discuss ion 
This study suggests that the higher the peak systolic pres- 
sure before metoprolol, the greater the improvement in left 
ventricular ejection fraction after 3 months of therapy. Adren- 
ergic activation, as reflected by coronary sinus norepinephrine 
(24) and heart rate, did not predict response. In addition, 
chamber size and left ventricular ejection fraction did not 
predict response. These data suggest that patients with a low 
ejection fraction, large volume and lower heart rate should not 
necessarily be excluded from beta-blockade or a priori be 
considered unlikely candidates to respond. In addition, we 
found that the higher the left ventricular end-diastolic pressure 
and the more prolonged the myocardial relaxation before 
metoprolol administration, the greater the reduction in end- 
diastolic pressure and the more improvement in myocardial 
relaxation after therapy. 
Predictors of systolic improvement. Previous investigators 
(5,6) have suggested that patients with heart failure who have 
coronary artery disease will not have as dramatic an improve- 
ment in left ventricular ejection fraction and reduction of left 
ventricular volume as patients with no coronary artery disease 
(5,6). In addition, these investigators found that the dose of 
beta-blocker administered may have an effect on functional 
outcome, with higher doses providing more systolic improve- 
ment than lower doses (6). In our study, we examined patients 
with heart failure but with no coronary artery disease, and each 
158 E ICHHORN ET AL. JACC Vol. 25, No. 1 
PREDICTORS OF IMPROVEMENT WITH BETA-BLOCKERS January, 1995:154-62 
.35 
.3 
.25 
.2 
0 
.15 0 
0 
Change .1 o 
In  LVEF  
.05, 
-.05, 
-.1£ 
Basel ine 
o r = 0 .003  
o p = 0 .99  
0 0 0 
0 0 
0 
0 
O O O 
O 
O O 
O o 
O 
200 400 600 800 100012001400160018002000 
Coronary  S inus  Norep lnephr lne  
(pg lml )  
.35 
.3. 
.25. 
.2. 
.15. 
Change 
in  LVEF  .1. 
.05, 
o. 
- .05 .  
-.1. 
0 r = 0 .19  
0 p = 0 .40  
0 
0 
oo  0 0 
~ o 
o ~ o 
0 0 0 0 
0 0 
0 
.05 .1 .15 .2 .25 .3 .35 .4 .45 
Base l ine  LVEF  
.35 
.3 
.25 
.2 
Chanoe 15 
i n  LVEF  .1 
.05 
0 
-.05 
-.1 
40 
o r = 0.11 
o p = 0 .62  
o 
o 
o O o 
o O 
o o ~ 
0 O0 
50 60 70 80 8o 100 11o 
Base l ine  Hear t  Rate  
(beats lmln)  
.3E 
.3, 
.25, 
.2. 
.15. 
Change 
i n  LVEF  .1. 
.05, 
01 
-.05, 
- 
120 150 
• • . i , , , . • • 
o r = 0 .04  
O p = 0 .87  
0 
O 
O O o 
O O 
O O 
O o 
~ o o 
g o 
200 250 
Base l ine  LV 
300 350 400 480 500 
End-D ias to l i c  Vo lume 
(ml )  
.3E 
.3 
.25 
.2 
.15 
Change .1 
In  LVEF  
.05 
o, 
-.05, 
-.1, 
100 
O 
o o 
| , , , p . , . , 
0 r = 0.04 | 
o p = 0 .87  [ 
[ 
O O O O 
v 
O 
O O 
O OD O 
0 0 
0 
150 200 
Baseline LV 
250 300 350 400 
End-Systo l i c  Vo lume 
(ml )  
received a relatively high dose of betaFblockade (50 mg of 
metoprolol twice daily). Thus, prediction of response may be 
partly dependent on etiology of disease and dose of drug 
administered. 
Two other ecent studies (7,8) have suggested that patients 
with the highest baseline heart rate, a reflection of adrenergic 
drive to the heart (24), will respond the best to beta-blockade. 
Our study did not confirm this because baseline heart rate and 
coronary sinus norepinephrine did not relate to changes in left 
ventricular ejection fraction after therapy (Fig. 2). One study 
(7) found that baseline heart rate was significantly lower in 
patients with heart failure who did not respond to metoprolol 
(defined by a change in ejection fraction <0.08) compared with 
those who did. When we used this same criteria for systolic 
improvement (change in ejection fraction ->0.08), we found no 
difference in baseline heart rate in those patients with versus 
Figure 2. Neither neuroadrenergic status (baseline coronary sinus 
norepinephrine and heart rate) nor left ventricular (LV) function and 
size (baseline l ft ventrieular ejection fraction [LVEF] and volumes) 
predicted systolic response tometoprolol. 
those without an improved ejection fraction (83 _+ 15 vs. 82 _+ 
14, respectively, p = 0.89). However, the patients in this 
previous study had ischemic cardiomyopathy, whereas our 
patients had no coronary disease. 
A recent histologic study of endomyocardial biopsy speci- 
mens (9) suggested that patients with the least fibrosis will 
respond best to therapy. Both this study and our data are 
consistent. These two studies imply that hose patients with the 
most residual viable myocardium ay be those who respond 
best to therapy. In the histologic study, patients with the least 
fibrosis had the greatest quantity of viable myocardium to 
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Table 2. Univariate and Multivariate Analysis of Diastolic Predictors ofImprovement With 
Metoprolol in 15 Patients 
Change in LVEDP Change in R 
No. of No. of 
Baseline Characteristic Pts r Value p Value Pts r Value p Value 
End-diastolic pressure 15 0.77 0.0008* 14 0.76 0.0017' 
Peak systolic pressure 15 0.20 0.49 14 0.03 0.92 
Tau (isovolumic relaxation rate) 14 0.60 0.02 14 0.70 0.006 
End-diastolic volume 15 0.39 0.15 14 0.50 0.07 
End-systolic volume 15 0.47 0.08 14 0.60 0.025 
Coronary sinus norepinephrine 15 0,42 0.12 14 0.30 0.29 
Heart rate 15 0,30 0.28 14 0.15 0.61 
Stroke work 15 0,09 0.76 14 0.08 0.79 
Peak +dP/dt 15 0,19 0.51 14 0.06 0.83 
Myocardial respiratory quotient 15 0,59 0.02 14 0.49 0.08 
Ejection fraction 15 0,28 0.31 14 0.46 0.10 
R (slope of tau-end-systolic pressure relation) 14 0.43 0.13 14 0.64 0.013 
*p < 0.05 by multivariate analysis. LVEDP = left ventricular end-diastolic pressure; other abbreviations as in Table 1. 
respond to therapy. Conversely, in our study, patients who 
have the highest systolic pressure (and highest peak +dP/dt, 
which was a weak univariate predictor) may be those with the 
Figure 3. Reduction in left ventricular (LV) end-diastolic pressure was 
correlated with baseline left ventricular end-diastolic pressure, isovolu- 
mic relaxation rates and transmyocardial respiratory quotient. A weak 
correlation that did not reach statistical significance was seen between 
the change in end-diastolic pressure and baseline left ventricular 
end-systolic volume. 
greatest amount of residual viable heart issue. Unfortunately, 
it is not feasible to perform biopsy in each patient before 
determining whether beta-blocker therapy will be successful at 
improving ejection fraction. However, it is very easy to mea- 
sure blood pressure to help predict response. 
If our hypothesis that patients with the most residual viable 
myocardium have the most improved systolic performance is 
correct, it is unclear why baseline jection fraction and systolic 
elastance were not predictors of response. However, the 
Beta-Blocker Evaluation of Survival Trial (BEST) (25), a 
National Heart, Lung, and Blood Institute and Veterans 
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Administration Cooperative trial, will prospectively examine 
several of these predictors, including presence of coronary 
disease, gender, baseline systolic pressure, ejection fraction, 
plasma norepinephrine and heart rate, to determine which 
patients will best respond to therapy. 
Predictors of diastolic improvement. There are no previ- 
ous studies to determine which patients will have the most 
diastolic improvement with beta-blockade. However, patients 
with the highest end-diastolic pressures and most prolonged 
isovolumetric relaxation are those who benefit he most. We 
previously showed (18) that a small improvement in contrac- 
tility may result in a large improvement in relaxation in 
patients with heart failure who have the most impaired relax- 
ation. In addition, we showed (23) that changes in myocardial 
relaxation correlate with concomitant changes in end-diastolic 
pressure in patients with heart failure. Thus, the most improve- 
ment in relaxation was seen in patients with the most impaired 
relaxation and highest end-diastolic pressures at baseline. 
We previously showed (3) a correlation between changes in 
Figure 4. Reduction in the slope of the isovolumetric elaxation 
rate-end-systolic pressure r lation (R) was correlated with baseline 
left ventricular (LV) end-diastolic pressure, isovolumetric elaxation 
rates and left ventricular volumes. A weak but not significant relation 
was seen between change in R and baseline transmyocardial respira- 
tory quotient. 
coronary sinus norepinephrine, a surrogate marker of adren- 
ergic drive to the heart, and transmyocardial respiratory quo- 
tient, a surrogate marker of substrate utilization in the heart 
(3). We demonstrated that progressive sympathetic a tivation 
in patients with heart failure may produce arelative increase in 
free fatty acid utilization and a reduction in carbohydrate 
utilization. When beta-blocking agents are given, substrate 
utilization shifts more to carbohydrate as coronary sinus 
norepinephrine d creases. In addition, we also showed (26) a 
relation between myocardial respiratory quotient and left 
ventricular end-diastolic pressure. Thus, as beta-blocking 
agents are given, sympathetic a tivity is reduced, and the heart 
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increases its relative carbohydrate utilization. As carbohydrate 
utilization increases, left ventricular end-diastolic pressure may 
decrease. Other investigators (27) have shown a blunting in 
end-diastolic pressure increase in the hypertrophied ischemic 
rat heart preparation when insulin and glucose are adminis- 
tered. On the basis of these data, a relation between substrate 
utilization and end-diastolic pressure is reasonable although 
the mechanism is not well understood. Thus, our finding that 
respiratory quotient isa weak (univariate) predictor of changes 
in end-diastolic pressure with metoprolol isnot unjustifiable. 
Study limitations. The greatest limitation of this study is 
the small sample size of only 24 patients. Because the sample 
size is small, and other studies have found other predictors, it
is possible that we could have produced a type I or II error 
(failure to find associations when present or finding a chance 
association that is spurious). Although the BEST trial will 
reexamine predictors of systolic improvement in a larger 
patient group, the evaluation of diastolic function is more 
difficult without subjecting a large number of patients to 
repeated catheterization. Noninvasive indexes of diastolic 
function are mostly load dependent. Thus, a large study of 
diastolic predictors is unlikely to be performed except in a 
cursory manner. 
Because patients with and without coronary artery disease 
respond ifferentially to beta-blocker therapy (5,6), we cannot 
extrapolate the results of this study to patients with coronary 
artery disease. In addition, because only one dose of metopro- 
lol was used in all patients, a different result may have occurred 
with lower dosages. Larger studies will help to elucidate which 
patients hould receive beta-blocking agents and which will 
best respond to this therapy. 
The comparison of left ventricular ejection fraction at 6 and 
3 months involves the use of two different echniques (angio- 
graphic left ventriculography and radionuclide ventriculogra- 
phy). The former makes geometric assumptions to assess 
ejection fraction (10,11), whereas the latter makes no geomet- 
ric assumptions (21,22). Despite these differences, these two 
techniques have been shown to correlate well with each other 
(22). In addition, a comparison of 36 studies of patients with 
dilated cardiorrlyopathy by radionuclide and angiographic 
techniques at our institution has shown excellent correlation 
(r = 0.78, SEE 0.06, p < 0.0001). Previous studies (28) have 
demonstrated no difference in ejection fraction with atrial 
pacing. However, in the present study ejection fraction at 3 
months was determined with atrial pacing and that at 6 months 
at rest. Some slight overestimation f rest ejection fraction at 
3 months may therefore be present, but this only makes the 
improvement seen from 3 to 6 months that much more 
significant. 
Conclusions. Improvement i  left ventricular ejection frac- 
tion in patients with nonischemic dilated cardiomyopathy 
receiving metoprolol was best predicted by baseline peak 
systolic pressure. Left ventrieular volume, ejection fraction or 
neurohormonal status did not predict who would best respond 
to this therapy. In addition, patients with the highest left 
ventricular end-diastolic pressure and most prolonged isovolu- 
metric relaxation were those who had the most diastolic 
improvement. Although patients with low peak systolic and 
end-diastolic pressures at baseline did not respond as well 
hemodynamically, these patients may still have received ben- 
efit from beta-blockade. It is still unclear whether beta- 
blockers prolong survival in patients with heart failure. The 
BEST trial (25) will evaluate survival and will examine whether 
there is an improvement i  mortality rate in patients with little 
hemodynamic improvement. 
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